August 12, 2021 -- Artiva Biotherapeutics plans to build a new 52,000-sq-ft facility in San Diego that will include research and process development laboratories and a multisuite, custom-built good manufacturing practices (GMP) manufacturing center.
The build-out is already underway and is anticipated to be completed in 2022. The facility will support NK and CAR-NK cell production for Artiva's pipeline development and clinical trial supply for the treatment of solid and hematological cancers, the company said.
Artiva's San Diego NK cell therapy research and GMP manufacturing facility. Image courtesy of Artiva Biotherapeutics.
The expansion builds on Artiva's current capabilities at its partner GC LabCell's facility in Korea.
Copyright © 2021 scienceboard.net